Home > TNF-alpha & > Thalidomide

Thalidomide

沙利度胺,酞胺哌啶酮,沙利度胺

Thalidomide 能抑制由bFGF或VEGF诱导的体内血管生成。

目录号
EY1823
EY1823
纯度
99.51%
99.51%
规格
200 mg
500 mg
原价
540
950
售价
540
950
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    (±)-Thalidomide is a selective inhibitor TNF-alpha(tumor necrosis factor alpha) with IC50 approaching to 2.0 nM.

  • 体外研究

  • 体内研究

    30% PEG400+0.5% Tween80+5% propylene glycol

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] D'Amato RJ, et al. Proc Natl Acad Sci U S A, 1994, 91(9), 4082-4085.
    [2] Fishman, S.J., et al. 1999. Angiogenesis. 3: 201-204.
    [3] Gockel, H.R., et al. 2004. J. Immunol. 172: 5103-5109.
    [4] Prommer, E.E. 2010. Am J Hosp Palliat Care. 27: 198-204.

    分子式
    C13H10N2O4    		 分子量
    258.23    		 CAS号
    50-35-1    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    >25 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    ≥2 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01485224 Hereditary Hemorrhagic Telangiectasia|Epistaxis Drug: Thalidomide IRCCS Policlinico S. Matteo Phase 2 2011-11-01 2016-02-27
    NCT00953615 Primary Sclerosing Cholangitis Drug: Thalidomide Mayo Clinic|Celgene Corporation Phase 2 2006-04-01 2012-01-24
    NCT02956538 Crohn Disease Drug: Thalidomide|Drug: placebo(for thalidomide) Sixth Affiliated Hospital, Sun Yat-sen University Early Phase 1 2016-10-01 2016-11-03
    NCT02995707 Thalassemia Drug: Thalidomide Xiao-Lin Yin|303rd Hospital of the People's Liberation Army Phase 2 2016-09-01 2017-03-21
    NCT00856804 Hepatitis C Drug: thalidomide Valme University Hospital|University of Seville Phase 2 2009-03-01 2009-03-05
    NCT00038233 Multiple Myeloma Drug: Thalidomide M.D. Anderson Cancer Center|Celgene Corporation Phase 3 1999-05-01 2012-07-27
    NCT00142116 Waldenstrom's Macroglobulinemia|Lymphoplasmacytic Lymphoma Drug: Thalidomide|Drug: Rituximab Steven P. Treon, MD, PhD|Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Cape Cod Healthcare Phase 2 2003-05-01 2014-05-08
    NCT02778893 NSCLC Drug: Conmana|Drug: Thalidomide Henan Provincial Hospital Phase 4 2016-03-01 2016-05-18
    NCT00657488 Multiple Myeloma Drug: Thalidomide Celgene Corporation Phase 2|Phase 3 2001-12-01 2016-11-29
    NCT01924624 Hepatocellular Carcinoma|Recurrence Drug: Thalidomide The First Affiliated Hospital of Xiamen University 2013-07-01 2013-08-15
    NCT01638078 Coronary Artery Disease Drug: Thalidomide|Drug: Placebo University of Roma La Sapienza Phase 4 2014-01-01 2013-03-06
    NCT01061866 Refractory Epilepsy Drug: 3-phthalimidoglutarimide (Thalidomide) National Institute of Neurology and Neurosurgery, Mexico|National Council of Science and Technology, Mexico Phase 1|Phase 2 2006-06-01 2010-02-05
    NCT00373646 MALT Lymphoma Drug: Thalidomide, Pharmion Medical University of Vienna Phase 2 2006-06-01 2009-06-17
    NCT03016000 Lymphoma, Large B-Cell, Diffuse Drug: Thalidomide|Other: Observation Nanfang Hospital of Southern Medical University Phase 3 2017-02-01 2017-01-07
    NCT00964496 Obscure Gastrointestinal Bleeding|Angiodysplasia|Gastric Antral Vascular Ectasia|Thalidomide Drug: Thalidomide|Drug: Iron Shanghai Jiao Tong University School of Medicine Phase 2 2004-11-01 2015-11-17
    NCT00921531 Hepatocellular Carcinoma Drug: Thalidomide|Drug: TACE Fudan University Phase 3 2009-06-01 2011-04-18
    NCT00966693 Myeloma Drug: Lenalidomide|Drug: Thalidomide|Drug: Dexamethasone M.D. Anderson Cancer Center|Celgene Phase 1|Phase 2 2009-08-01 2016-12-28
    NCT02754960 Gastrointestinal Hemorrhage|Vascular Malformation Drug: Thalidomide|Drug: Placebo Shanghai Jiao Tong University School of Medicine Phase 2 2010-03-01 2016-04-26

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：